• 2019
  Dufour N, Delattre R, Chevallereau A, Ricard JD, Debarbieux L, Phage Therapy of Pneumonia Is Not Associated with an Overstimulation of the Inflammatory Response Compared to Antibiotic Treatment in Mice, Antimicrob. Agents Chemother. 2019 Aug;63(8).
• 2019
  De Sordi L, Lourenço M, Debarbieux L, The Battle Within: Interactions of Bacteriophages and Bacteria in the Gastrointestinal Tract, Cell Host Microbe 2019 02;25(2):210-218.
• 2018
  Debarbieux L, Forterre P, Krupovic M, Kutateladze M, Prangishvili D, Centennial celebration of the bacteriophage research, Res. Microbiol. 2018 11;169(9):479-480.
• 2018
  De Sordi L, Lourenço M, Debarbieux L, “I will survive”: A tale of bacteriophage-bacteria coevolution in the gut, Gut Microbes 2019;10(1):92-99.
• 2018
  Lourenço M, De Sordi L, Debarbieux L, The Diversity of Bacterial Lifestyles Hampers Bacteriophage Tenacity, Viruses 2018 06;10(6).
• 2018
  Forti F, Roach DR, Cafora M, Pasini ME, Horner DS, Fiscarelli EV, Rossitto M, Cariani L, Briani F, Debarbieux L, Ghisotti D, Design of a Broad-Range Bacteriophage Cocktail That Reduces Pseudomonas aeruginosa Biofilms and Treats Acute Infections in Two Animal Models, Antimicrob. Agents Chemother. 2018 Jun;62(6).
• 2017
  De Sordi L, Khanna V, Debarbieux L, The Gut Microbiota Facilitates Drifts in the Genetic Diversity and Infectivity of Bacterial Viruses, Cell Host Microbe 2017 Nov;.
• 2017
  Roach DR, Leung CY, Henry M, Morello E, Singh D, Di Santo JP, Weitz JS, Debarbieux L, Synergy between the Host Immune System and Bacteriophage Is Essential for Successful Phage Therapy against an Acute Respiratory Pathogen, Cell Host Microbe 2017 Jul;22(1):38-47.
• 2017
  Dufour N, Delattre R, Ricard JD, Debarbieux L, The Lysis of Pathogenic Escherichia coli by Bacteriophages Releases Less Endotoxin Than by β-Lactams, Clin. Infect. Dis. 2017 Jun;64(11):1582-1588.
• 2017
  Blasdel BG, Chevallereau A, Monot M, Lavigne R, Debarbieux L, Comparative transcriptomics analyses reveal the conservation of an ancestral infectious strategy in two bacteriophage genera, ISME J 2017 May;.
• 2017
  Galtier M, De Sordi L, Sivignon A, de Vallée A, Maura D, Neut C, Rahmouni O, Wannerberger K, Darfeuille-Michaud A, Desreumaux P, Barnich N, Debarbieux L, Bacteriophages targeting adherent invasive Escherichia coli strains as a promising new treatment for Crohn’s disease, J Crohns Colitis 2017 Jan;.
• 2016
  Dufour N, Clermont O, La Combe B, Messika J, Dion S, Khanna V, Denamur E, Ricard JD, Debarbieux L,, Bacteriophage LM33_P1, a fast-acting weapon against the pandemic ST131-O25b:H4 Escherichia coli clonal complex, J. Antimicrob. Chemother. 2016 Jul;.
• 2016
  Chevallereau A, Blasdel BG, De Smet J, Monot M, Zimmermann M, Kogadeeva M, Sauer U, Jorth P, Whiteley M, Debarbieux L, Lavigne R, Next-Generation “-omics” Approaches Reveal a Massive Alteration of Host RNA Metabolism during Bacteriophage Infection of Pseudomonas aeruginosa, PLoS Genet. 2016 Jul;12(7):e1006134.
• 2016
  Dufour N, Henry M, Ricard JD, Debarbieux L, Commentary: Morphologically Distinct Escherichia coli Bacteriophages Differ in Their Efficacy and Ability to Stimulate Cytokine Release In Vitro, Front Microbiol 2016;7:1029.
• 2016
  Galtier M, De Sordi L, Maura D, Arachchi H, Volant S, Dillies MA, Debarbieux L, Bacteriophages to reduce gut carriage of antibiotic resistant uropathogens with low impact on microbiota composition, Environ. Microbiol. 2016 Mar;.
• 2015
  Dufour N, Debarbieux L, Fromentin M, Ricard JD, Treatment of Highly Virulent Extraintestinal Pathogenic Escherichia coli Pneumonia With Bacteriophages, Crit. Care Med. 2015 Jun;43(6):e190-8.
• 2015
  Henry M, Bobay LM, Chevallereau A, Saussereau E, Ceyssens PJ, Debarbieux L, The search for therapeutic bacteriophages uncovers one new subfamily and two new genera of Pseudomonas-infecting Myoviridae, PLoS ONE 2015;10(1):e0117163.
• 2015
  Pirnay JP, Blasdel BG, Bretaudeau L, Buckling A, Chanishvili N, Clark JR, Corte-Real S, Debarbieux L, Dublanchet A, De Vos D, Gabard J, Garcia M, Goderdzishvili M, Górski A, Hardcastle J, Huys I, Kutter E, Lavigne R, Merabishvili M, Olchawa E, Parikka KJ, Patey O, Pouilot F, Resch G, Rohde C, Scheres J, Skurnik M, Vaneechoutte M, Van Parys L, Verbeken G, Zizi M, Van den Eede G, Quality and safety requirements for sustainable phage therapy products, Pharm. Res. 2015 Jul;32(7):2173-9.
• 2014
  Saussereau E, Vachier I, Chiron R, Godbert B, Sermet I, Dufour N, Pirnay JP, De Vos D, Carrié F, Molinari N, Debarbieux L, Effectiveness of bacteriophages in the sputum of cystic fibrosis patients, Clin. Microbiol. Infect. 2014 Dec;20(12):O983-90.
• 2014
  Debarbieux L, Bacterial sensing of bacteriophages in communities: the search for the Rosetta stone, Curr. Opin. Microbiol. 2014 Aug;20:125-30.
• 2013
  Debarbieux L, Saussereau E, Maura D, [Phagotherapy: a nightmare for bacteria, a dream for physicians?], Biol Aujourdhui 2013;207(3):181-90.
• 2013
  Henry M, Lavigne R, Debarbieux L, Predicting in vivo efficacy of therapeutic bacteriophages used to treat pulmonary infections, Antimicrob. Agents Chemother. 2013 Dec;57(12):5961-8.
• 2013
  Matos RC, Lapaque N, Rigottier-Gois L, Debarbieux L, Meylheuc T, Gonzalez-Zorn B, Repoila F, Lopes Mde F, Serror P, Enterococcus faecalis prophage dynamics and contributions to pathogenic traits, PLoS Genet. 2013 Jun;9(6):e1003539.
• 2013
  Huys I, Vaneechoutte M, Verbeken G, Debarbieux L, Key issues in phage therapy: a report of a dedicated workshop at the Viruses of Microbes II meeting, Res. Microbiol. 2013 Sep;164(7):806-10.
• 2013
  Saussereau EL, Roussel D, Diallo S, Debarbieux L, Edelman A, Sermet-Gaudelus I, Characterization of nasal potential difference in cftr knockout and F508del-CFTR mice, PLoS ONE 2013;8(3):e57317.
• 2012
  Ceyssens PJ, Aertsen A, Donovan DM, Lavigne R, Sullivan MB, Debarbieux L, Vaneechoutte M, Meeting report of the European Molecular Biology Organization (EMBO) Symposium ‘Viruses of Microbes II’, Brussels, July 2012, Res. Microbiol. 2013 Sep;164(7):799-805.
• 2012
  Henry M, Debarbieux L, Tools from viruses: bacteriophage successes and beyond, Virology 2012 Dec;434(2):151-61.
• 2012
  Maura D, Debarbieux L, On the interactions between virulent bacteriophages and bacteria in the gut, Bacteriophage 2012 Oct;2(4):229-233.
• 2012
  Maura D, Galtier M, Le Bouguénec C, Debarbieux L, Virulent bacteriophages can target O104:H4 enteroaggregative Escherichia coli in the mouse intestine, Antimicrob. Agents Chemother. 2012 Dec;56(12):6235-42.
• 2012
  Saussereau E, Debarbieux L, Bacteriophages in the experimental treatment of Pseudomonas aeruginosa infections in mice, Adv. Virus Res. 2012;83:123-41.
• 2011
  Maura D, Morello E, du Merle L, Bomme P, Le Bouguénec C, Debarbieux L, Intestinal colonization by enteroaggregative Escherichia coli supports long-term bacteriophage replication in mice, Environ. Microbiol. 2012 Aug;14(8):1844-54.
• 2011
  Maura D, Debarbieux L, Bacteriophages as twenty-first century antibacterial tools for food and medicine, Appl. Microbiol. Biotechnol. 2011 May;90(3):851-9.
• 2011
  Morello E, Saussereau E, Maura D, Huerre M, Touqui L, Debarbieux L, Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: first steps towards treatment and prevention, PLoS ONE 2011;6(2):e16963.
• 2010
  Pirnay JP, De Vos D, Verbeken G, Merabishvili M, Chanishvili N, Vaneechoutte M, Zizi M, Laire G, Lavigne R, Huys I, Van den Mooter G, Buckling A, Debarbieux L, Pouillot F, Azeredo J, Kutter E, Dublanchet A, Górski A, Adamia R, The phage therapy paradigm: prêt-à-porter or sur-mesure?, Pharm. Res. 2011 Apr;28(4):934-7.
• 2010
  Debarbieux L, Leduc D, Maura D, Morello E, Criscuolo A, Grossi O, Balloy V, Touqui L, Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections, J. Infect. Dis. 2010 Apr;201(7):1096-104.
• 2008
  Debarbieux L, [Experimental phage therapy in the beginning of the 21st century], Med Mal Infect 2008 Aug;38(8):421-5.
• 2008
  Debarbieux L, Dublanchet A, Patey O, [Organizers’ report], Med Mal Infect 2008 Aug;38(8):410-4.
• 2006
  Cescau S, Debarbieux L, Wandersman C, Probing the in vivo dynamics of type I protein secretion complex association through sensitivity to detergents, J. Bacteriol. 2007 Mar;189(5):1496-504.
• 2005
  Huber D, Cha MI, Debarbieux L, Planson AG, Cruz N, López G, Tasayco ML, Chaffotte A, Beckwith J, A selection for mutants that interfere with folding of Escherichia coli thioredoxin-1 in vivo, Proc. Natl. Acad. Sci. U.S.A. 2005 Dec;102(52):18872-7.
• 2003
  Létoffé S, Debarbieux L, Izadi N, Delepelaire P, Wandersman C, Ligand delivery by haem carrier proteins: the binding of Serratia marcescens haemophore to its outer membrane receptor is mediated by two distinct peptide regions, Mol. Microbiol. 2003 Oct;50(1):77-88.
• 2001
  Debarbieux L, Wandersman C, Folded HasA inhibits its own secretion through its ABC exporter, EMBO J. 2001 Sep;20(17):4657-63.
• 2000
  Debarbieux L, Beckwith J, On the functional interchangeability, oxidant versus reductant, of members of the thioredoxin superfamily, J. Bacteriol. 2000 Feb;182(3):723-7.
• 1999
  Debarbieux L, Beckwith J, Electron avenue: pathways of disulfide bond formation and isomerization, Cell 1999 Oct;99(2):117-9.
• 1998
  Debarbieux L, Beckwith J, The reductive enzyme thioredoxin 1 acts as an oxidant when it is exported to the Escherichia coli periplasm, Proc. Natl. Acad. Sci. U.S.A. 1998 Sep;95(18):10751-6.
• 1997
  Debarbieux L, Bohin A, Bohin JP, Topological analysis of the membrane-bound glucosyltransferase, MdoH, required for osmoregulated periplasmic glucan synthesis in Escherichia coli, J. Bacteriol. 1997 Nov;179(21):6692-8.
• 1993
  Loubens I, Debarbieux L, Bohin A, Lacroix JM, Bohin JP, Homology between a genetic locus (mdoA) involved in the osmoregulated biosynthesis of periplasmic glucans in Escherichia coli and a genetic locus (hrpM) controlling pathogenicity of Pseudomonas syringae, Mol. Microbiol. 1993 Oct;10(2):329-40.